It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mutations in the ubiquitously expressed pre-mRNA processing factor (PRPF) 31 gene, one of the most common causes of dominant form of Retinitis Pigmentosa (RP), lead to a retina-specific phenotype. It is uncertain which retinal cell types are affected and animal models do not clearly present the RP phenotype observed in PRPF31 patients. Retinal organoids and retinal pigment epithelial (RPE) cells derived from human-induced pluripotent stem cells (iPSCs) provide potential opportunities for studying human PRPF31-related RP. We demonstrate here that RPE cells carrying PRPF31 mutations present important morphological and functional changes and that PRPF31-mutated retinal organoids recapitulate the human RP phenotype, with a rod photoreceptor cell death followed by a loss of cones. The low level of PRPF31 expression may explain the defective phenotypes of PRPF31-mutated RPE and photoreceptor cells, which were not observed in cells derived from asymptomatic patients or after correction of the pathogenic mutation by CRISPR/Cas9. Transcriptome profiles revealed differentially expressed and mis-spliced genes belonging to pathways in line with the observed defective phenotypes. The rescue of RPE and photoreceptor defective phenotypes by PRPF31 gene augmentation provide the proof of concept for future therapeutic strategies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France (GRID:grid.418241.a) (ISNI:0000 0000 9373 1902)
2 Université Paris-Saclay, Paris-Saclay Institute of Neuroscience, CERTO-Retina France, CNRS, Saclay, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
3 University of Pittsburgh School of Medicine, Department of Ophthalmology, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
4 Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France (GRID:grid.418241.a) (ISNI:0000 0000 9373 1902); University of Pittsburgh School of Medicine, Department of Ophthalmology, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000); Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Centre de référence maladies rares REFERET, Paris, France (GRID:grid.415610.7) (ISNI:0000 0001 0657 9752)
5 Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France (GRID:grid.418241.a) (ISNI:0000 0000 9373 1902); Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Centre de référence maladies rares REFERET, Paris, France (GRID:grid.415610.7) (ISNI:0000 0001 0657 9752)